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Summary
Background: Acquired hemophilia is a rare condition
which can be associated with lymphoproliferative disease.
Case Report: Eleven years after the diagnosis of immuno-
cytoma had been made, a 72-year-old man developed a
high-titer factor VIII inhibitor. At this time, the lymphoma
was without significant progress and there was no para-
protein in the serum. Partial thromboplastin time (PTT)
was 83 s, factor-VIII clotting activity was <1%, and inhibi-
tor level was 50.4 Bethesda units. The patient presented
with spontaneous hematomas in the skin and musculature
of the extremities. Following combination chemotherapy
with cyclophosphamide, vincristine and prednisolone
(COP), there was a prompt disappearance of the inhibitor
and normalization of coagulation; however, the patient
developed serious infectious complications. When the
inhibitor recurred he was treated with low-dose cyclo-
phosphamide and prednisolone. This time there was a
more delayed response, but the inhibitor disappeared
again completely. Two months after cessation of therapy,
there was again relapse. Conclusion: Causal relationship
between lymphoma and acquired hemophilia remains
speculative. At least in some cases of factor VIII inhibitors
associated with malignant disease, immunosuppressive
therapy may be sufficient to suppress the inhibitor.
Schlüsselwörter
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Zusammenfassung
Hintergrund: Die erworbene Hämophilie ist selten und
kann mit lymphoproliferativen Erkrankungen assoziiert
sein. Kasuistik: Elf Jahre nach Diagnosestellung eines
Immunozytoms entwickelte ein 72jähriger Mann einen
hochtitrigen Faktor-VIII-Inhibitor. Zu dieser Zeit zeigte das
Lymphom keinen eindeutigen Progreß und im Serum war
kein Paraprotein nachweisbar.Die partielleThromboplastin-
zeit (PTT) betrug 83 s, Faktor VIII: C war <1% und der Inhi-
bitor-Titer lag bei 50,4 Bethesda-Einheiten. Der Patient
entwickelte spontane Hämatome an Haut und Muskulatur
der Extremitäten. Nach Polychemotherapie mit Cyclo-
phosphamid, Vincristin und Prednisolon (COP) kam es zu
einem raschen Verschwinden des Inhibitors und zu einer
Normalisierung der Gerinnung, der Patient entwickelte
jedoch schwere Infektkomplikationen. Ein Rezidiv wurde
mit niedrig dosiertem Cyclophosphamid und Prednisolon
behandelt. Das Ansprechen schien protrahiert, aber der
Inhibitor verschwand wieder vollständig. Zwei Monate nach
Therapiebeendigung zeichnete sich ein neues Rezidiv ab.
Schlußfolgerung: Ob ein Kausalzusammenhang zwischen
dem Lymphom und der erworbenen Hämophilie besteht,
kann nur spekuliert werden. Zumindest in einigen Fällen
von Faktor-VIII-Antikörpern, die mit malignen Erkran-
kungen assoziiert sind, kann eine immunsuppressive
Therapie ausreichen, um den Inhibitor zu unterdrücken.
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Introduction
Acquired hemophilia due to factor VIII inhibitor is a rare
clinical condition. The incidence is reported as about one per
million annually [1, 2]. But it represents the most common type
of spontaneously acquired inhibitors against a clotting factor
[3]. Both sexes are affected equally [1, 4]. The incidence in-
creases with age, the majority of patients being over 50 years of
age.There is a second small peak of incidence in the 3rd decade,
accounted for by women affected around parturition [4].
A wide range of associated conditions has been described in
the literature. In a large survey [4] of 215 patients with factor
VIII inhibitors, 18% had concomitant autoimmune disorders
like rheumatoid arthritis and systemic lupus erythematosus,
7% were postpartum women, 7% had malignancies, 5% had
been trated with drugs (penicillin, phenytoin), 5% had skin dis-
orders like psoriasis and pemphigus, and 12% had various con-
ditions like asthma, multiple transfusions, diabetes or hepatitis.
In 46%, no associated disease could be identified. Beside this
case series, both various solid tumors [5, 6] and hematologic
malignancies [3, 7–14] like plasma cell dyscrasias and lympho-
proliferative disease are reported frequently in the literature in
conjunction with factor VIII inhibitors. Whereas in autoim-
mune disorders and hematologic malignancies a causal relation
between autoantibody formation and associated disease seems
possible, as there is both a plausible pathogenesis and clinical
evidence [3, 15], the nature of this correlation is less clear 
for most of the other conditions. And the fact that most of 
them tend to occur in the elderly may indicate a coincidental
relationship [1].
Case Report
A 72-year-old man was admitted to the hospital because of spontaneous
hematomas of the upper and lower extremities. Eleven years before admis-
sion, the diagnosis of a low-grade non-Hodgkin’s lymphoma, specified as
nonsecretory immunocytoma stage IV A (Binet stage A) with enlargement
of axillary, supraclavicular, mediastinal and paraaortal lymph nodes and
infiltration of bone marrow, had been made.The patient had no treatment,
and during regular follow-up no progression of the lymphoma was ob-
served. He had developed anteroseptal myocardial infarction 21 years
before admission and since then suffered from stable angina pectoris,
which was controlled by bisoprolol and isosorbide dinitrate. In addition he
took acetylsalicylic acid 100 mg daily. He had a history of psoriasis, which
was without any activity at admission. He had scmoked until 11 years
before admission.
Three weeks before admission he consecutively developed hematomas of
the left elbow, right upper arm, left thigh, right gluteal region and left fore-
arm, which had led to tension of the musculature with imminent compart-
ment syndrome. All hematomas developed overnight without adequate
trauma. The patient’s general practitioner found a prolonged partial
thromboplastin time (PTT), which until then had been normal in all
routine controls. Intravenous injection of vitamin K 2 days before admis-
sion had been without effect on PTT. On admission, the patient was well
except for a mild exertional dyspnea. The musculature of the left forearm
was tense and tender, but radial pulses were palpable on either side. No
petechial bleeding could be found. There was no past or family history of
bleeding tendency. The temperature was 37 ºC, the pulse was 76/min, and
blood pressure was 120/70 mm Hg. On auscultation, lung and heart sounds
were clear. The abdomen was soft without evidence of ascites or organo-
megaly. Small lymph nodes could be palpated in both axillae and the right
supraclavicular region. The bleeding time, measured with the standardized
Surgicutt device, was normal (4 min). The urine was positive (+++) for
blood. Laboratory tests were performed (table 1). The electrocardiogram
was without pathologic finding. A chest radiograph showed slight left
ventricular enlargement and pleural adhesions at the base of the right 
lung, which was known from previous films.
Two units of fresh frozen plasma were given on the 1st hospital day and
were without effect on the PTT. Oral antibiotic treatment with cefaclor
was initiated to prevent superinfection of hematomas.The left forearm was
cooled with ice to prevent further swelling and compartment syndrome.
While microscopical examination of a blood smear was normal, immuno-
phenotyping of the peripheral blood by flow cytometry showed elevation
of CD19+ B cells (69% of mononuclear cells CD19+; 21% CD3+) and
light-chain restriction in CD19+ B cells (47% c/CD19+; 1% c/CD19+),
consistent with the presence of a malignant clone of B cells in the peri-
pheral blood.An abdominal ultrasound scan showed multiple concrements
in the gallbladder. A CT scan of the abdomen showed multiple paraaortic
and paracaval lymph nodes enlarged slightly above 1 cm. A CT scan of the
thorax showed multiple mediastinal lymph nodes also at the size of 1 cm.
On the 6th hospital day, factor VIII clotting activity (factor VIII:C) was
lower than 1% (normal range 70–150%) and could not be raised sub-
stantially immediately and 2 h after mixing of patient and normal plasma,
indicating the presence of a factor VIII inhibitor in the patient plasma.
The inhibitor level was determined with 50.4 Bethesda units. PTT and
factor VIII:C did not change substantially 2, 4, and 10 h after intravenous
infusion of desmopressin acetate (36 g in 30 min). The von Willebrand
factor activity was 152%. The diagnosis of acquired hemophilia caused by
factorVIII inhibitor possibly related to low-grade non-Hodgkin’s lymphoma
(immunocytoma) was made.
On the 8th hospital day, immunosuppressive therapy with steroids (pred-
nisolone 100 mg/day) was initiated and chlorambucil (20 mg on day 8 and
15 mg on day 9) was given to treat the underlying malignant disease. To
prevent further and probably life-threatening bleeding, 3,000 IU of acti-
vated prothrombin complex concentrate with factor VIII inhibitor by-
passing activity (FEIBA S-TIM 4 Immuno®, Baxter, Vienna, Austria) were
given intravenously as a bolus on days 10–14. As only a slight decrease of
PTT could be achieved by these measures, the need for a more intensive
antineoplastic therapy was seen. On the 12th hospital day, polychemo-
therapy was initiated according to the COP regimen (cyclophosphamide
400 mg/m2 i.v., days 1–5; vincristine 2 mg i.v., day 1; prednisolone 100 mg
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Table 1. Laboratory values on first admission
Patient Normal
value value
White cell count/nl 12.1 4.0–10.0
Differential count
Neutrophils, % 42 50–70
Lymphocytes, % 47 25–40
Monocytes, % 5 2–10
Eosinophils, % 2 0–5
Basophils, % 1 0–1
Hemoglobin, g/dl 11.7 14.0–18.0
Platelet count/nl 168 150–400
INR 0.9
PTT, s 83 26–36
Creatine, mg/dl 1.2 0.7–1.2
Sodium, mmol/l 142 135–145
Potassium, mmol/l 3.9 3.5–5.0
Total protein, g/dl 6.9 6.1–8.2
Serum electrophoresis
Albumin, % 66.1 55.0–69.0
1-Globulin, % 4.1 1.6–5.8
2-Globulin, % 7.8 5.9–11.1
-Globulin, % 13.0 8.0–12.0
-Globulin, % 9.0a 11.0–20.0
C-reactive protein, mg/dl 0.7 0.0–0.8
2-Microglobulin, mg/l 1.8 0.8–2.5
Immunoglobulin
G, mg/l 507 700–1,600
A, mg/l 60 70–400
M, mg/l 90 40–230
Thyroid-stimulating hormone, mE/l 1.6 0.2–3.5
Cardiolipin antibodies, GPL-U/ml 2 0–12
a Without monoclonal component.
per os days 1–5). Consecutively, PTT dropped to 45 s on the 20th hospital
day without clinical signs of further bleeding, and the patient could be
discharged. Steroid therapy was continued with prednisolone 100 mg/day.
On day 52 after first admission, the patient presented without any further
bleeding and with a normal PTT. Prednisolone was reduced to 50 mg/day.
The second course of COP chemotherapy was given in an outpatient
setting in our hematologic clinic. On day 67, the patient was admitted to
the hispital with bilateral atypical pneumonia and exanthema of the right
inguinal region and scrotum which was suspicious for herpes simplex.
White blood count was 1.1/nl. Prednisolone was tapered, 30 g immuno-
globulins and broad-spectrum antimicrobial therapy were given intra-
venously. Neutropenia resolved on the 2nd day, but the clinical condition
improved slowly. On day 101, factor VIII:C was 57.0%, consistent with low-
titer factor VIII inhibitor. On bone marrow aspiration, a focal infiltration
by lymphocytes (5%) showing morphologic characteristics of immuno-
cytes was found. Immunophenotyping of bone marrow blood confirmed
light-chain restriction in CD19+ lymphocytes (15% c/CD19+; < 1%
c/CD19+), consistent with infiltration of the bone marrow by the malig-
nant B-cell clone. As there was no further bleeding, a decision for a wait-
and-see strategy was made.
Consecutively, PTT slowly increased and exceeded the upper limit of
normal on day 120, but factor VIII:C was 85% and the patient was well
without bleeding.
On day 165, PTT was 59 s, factor VIII:C had decreased to 2% and factor
VIII inhibitor level was 1.6 Bethesda units. Although there was no bleed-
ing, the need for therapy was seen. Regarding the severe infectious
complications of polychemotherapy and the lack of significant lymphoma
progression, a decision was made for a mild nonmyelotoxic immuno-
suppressive therapy with cyclophosphamide 100 mg per os, days 1–4, and
prednisolone 100 mg per os, days 1–4, q15 days. Six courses of this therapy
were given starting on days 175, 189, 203, 217, 246, and 260. During this
period, PTT slowly decreased without reaching normal range, factor
VIII:C rose to 65% on day 246 with undetectable factor VIII inhibitor, and
no bleeding, neutropenia, or infectious complications developed. On
reevaluation on day 368, the PTT showed a tendency to increase (45 s),
indicating recurrence of factor VIII inhibitor (fig. 1).
Discussion
Factor VIII inhibitors bind to functional epitopes or antigeneic
sites of the factor VIII molecule, preventing interaction with
other clotting factors or increasing neutralization [17]. The
development of a factor VIII inhibitor has serious conse-
quences. In a large survey [4], major bleeding occurred in 87%
of patients, and 22% died either directly or indirectly as a
consequence of having the inhibitor. The most common pre-
sentation is bleeding into the skin, soft tissue and muscles,
which can lead to compartment syndrome.There can be muco-
sal bleeding like epistaxis, gastrointestinal bleeding or hema-
turia. In elderly patients with concomitant cardiac disease the
resulting anemia may lead to angina pectoris or signs of heart
failure. There may be iatrogenic bleeding after invasive diag-
nostic procedures, intravenous catheter placement and surgery
[1]. Retroperitoneal and intraperitoneal hemorrhage is often
fatal [4, 16]. For unknown reasons, joint bleeding seems to be
rare in contrast to congenital hemophilia [2].
The hallmark of laboratory diagnosis of factor VIII inhibitors
is prolongation of the PTT, whereas the prothrombin time is
normal. Factor VIII:C is measured in a mixing assay using
factor VIII-deficient plasma. Mixing of normal and patient
plasma can distinguish between primary factor deficiency (like
in congenital hemophilia and von Willebrand’s disease) and
secondary deficiency due to an inhibitor. While addition of
normal plasma to factor-deficient plasma normalizes the PTT,
mixing of normal plasma with plasma containing an inhibitor
fails to correct PTT. A widely accepted method for quantifying
the inhibitor is the Bethesda assay [17, 18]. Dilutions of patient
plasma are incubated with normal pooled plasma for 2 h at
37 ºC, and residual F VIII:C is measured and expressed as per-
centage of a control assay. Results are converted to antibody
units using a conversion graph and multiplying according to
the dilutions used. One Bethesda unit (BU) represents the
amount of antibody that yields 50% residual activity in the test
system. Quantification of the inhibitor may be an important
prerequisite for treatment decisions [1].
Management of patients with factor VIII inhibitors has two
objectives: (1) therapy and prevention of acute bleeding, and
(2) reduction and elimination of the autoantibody [1].
The therapy of acute bleeding requires a variety of expensive
blood products dependent on the titer of inhibitor (table 2). In
patients with a low-titer inhibitor, elevation of factor VIII level
with desmopressin (DDAVP) or substitution of human factor
VIII may be sufficient. In patients with higher titers the substi-
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Fig. 1. PTT and chemotherapy.
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tution of porcine factor VIII, which interacts less strongly with
autoantibodies and thus leads to higher levels of circulating,
F VIII:C [19, 20], may be indicated. Alternatives are the use of
recombinant factor VIIa [21], which activates factor X when
complexed with tissue factor at the site of injury, thus by-
passing deficient factor VIII and resulting in local thrombin
formation; or of activated prothrombin complex preparation,
which likewise bypass factor VIII. Factor substitution can be
preceded by plasmapheresis or immunoadsorption if available.
Another method to decrease the inhibitor level in the phase 
of acute bleeding is the intravenous infusion of high-dose
immunoglobulins (e.g., 1 g/kg daily for 2 days), as these prepa-
rations contain anti-idiotypic antibodies, which are directed
against the patient’s autoantibody [22].
It is still under debate whether the factor VIII inhibitor can 
be reduced and possibly eliminated by immunosuppressive
therapy with steroids and/or cytotoxic drugs. Approximately
on third of patients who receive supportive therapy only
(transfusion of blood and factor concentrates) show spon-
taneous remission. These are mostly patients in pregnancy and
postpartum or without underlying disease and low-titer inhibi-
tors, who rarely develop life-threatening bleeding [2, 4]. Fol-
lowing this observation, some authors tend to regard acquired
hemophilia as a rather benign condition not warranting, some
authors tend to regard acquired hemophilia as a rather benign
condition not warranting the use of potent immunosuppressive
and possibly oncogenic drugs. However, spontaneous loss of
the antibody is unpredictable, may take months or years during
which the patient is at risk for serious hemorrhage, and sup-
portive therapy with blood products is expensive. Therefore,
efforts to reduce or eliminate the antibody are justified.A large
survey [4] showed that 56% of patients had benefit from drug
therapy (either steroids or cytotoxic drugs or both), suggesting
that immunosuppressive therapy accelerates inhibitor dis-
appearance compared with supportive therapy alone. There is
much anecdotal evidence for the efficacy of immunosuppres-
sive therapy [3, 5, 8–10,23].A prospective randomized trial [16,
24] showed the efficacy of prednisone and cyclophosphamide
both alone and in combination. In this trial, responders to drug
therapy had lower mean factor VIII antibody titers and higher
mean factor VIII levels compared to non responders.
Based on this evidence, it is recommended [1] to administer
steroids as a 1st-line treatment (prednisolone 1 mg/kg for
3 weeks, then taper). If the inhibitor persists, cytotoxic drugs
like cyclophosphamide (2 mg/kg orally for 3–6 weeks) or
azathioprine (2 mg/kg/day orally) should be given as 2nd-line
treatment either alone, in combination with steroids, or in com-
bination chemotherapy like the COP regimen. Should anti-
bodies persist, cyclosporine is another option of proven
efficacy for the 3rd-line therapy (up to 5 mg/kg/day yielding
plasma levels of 150–350 ng/ml). Therapy should be continued
until complete normalization of coagulation, and retreatment
may be needed if inhibitors recur [23].
In our case there are two disorders, which are regarded as
possibly connected to factor VIII antibody formation: (1)
psoriasis, which was without significant activity at the point of
antibody appearance and during all follow-ups, and (2) low-
grade B-cell lymphoma, which had been diagnosed 11 years
prior to the appearance of factor VIII antibodies and had been
without significant progress apart from the development of an
immunoglobulin deficiency. Furthermore, there was no mono-
clonal gammopathy, to which the activity against factor VIII
could have been ascribed. Antibodies against factor VIII are
known to be predominantly composed of immunoglobulin G
[18]. In a case of Waldenström’s disease, factor VIII antibodies
have been shown to be polyclonal IgG molecules and thus not
to be part of the IgM paraprotein [14].
In our case, it can only be speculated about the nature of the
relationship between factor VIII antibodies and lymphoma.
Autoantibodies can arise from malignant B cells or from a nor-
mal polyclonal lymphatic population. Autoantibody formation
in normal lymphocytes can be triggered by the presence of a
malignant cell clone. Alternatively, both disorders only co-
incidentally coexist in one individual.
With the intention to treat ‘underlying’ disease the patient
received two courses of COP polychemotherapy with prompt
normalization of coagulation parameters but with serious infec-
tious complications.At recurrence of the inhibitors he received
immunosuppressive therapy with prednisolone and cyclophos-
phamide with a more delayed response. Both therapies were
effective but neither completely eradicated the inhibitor.
Under either therapy the lymphoma showed no significant
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Titer, Bleeding Treatment
BU
< 5 not limb- or a) DDAVP, 0.3 g/kg i.v. over 20 min. If no response, give
life-threatening b) Recombinant human F VIII, 100 U/kg, then 10 U/kg/h, or
c) Porcine F VIII, 0–100 U/kg, then 4 U/kg/h
5–30 serious a) Porcine F VIII, 50–100 U/kg, then 4 U/kg/h, or
b) Recombinant human F VIIa, 90 g/kg every 2–3 h, or 
c) Activated prothrombin complex concentrate, 50–75 U/kg every 8–12 h
> 30 serious a) Porcine F VIII, 100–200 U/kg, then 10 U/kg/h, or
b) Recombinant human F VIIa, 90 g/kg every 2–3 h, or 
c) Activated prothrombin complex concentrate, 50–100 U/kg every 8–12 h
Table 2. Treatment of
acute bleeding
change. We conclude that, at least in some cases of factor VIII
inhibitors associated with malignancy, immunosuppressive
therapy may be sufficient to suppress the inhibitor, and anti-
neoplastic chemotherapy is not warranted unless indicated by
the course of malignant disease itself.
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